Name

Becanex

Legal name

Becanex GmbH

Website

https://becanex.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical cannabis extract sales: Becanex manufactures and sells THC-dominant and CBD-dominant pharmaceutical concentrates (PIEX product portfolio) to compounding pharmacies in Germany and across Europe. Products include PIEX 1, PIEX 2 (70% THC, Strawberry OG strain), PIEX 3 (62% CBD, God Bud strain), PIEX 4 (70% THC), PIEX 6 (70% THC), and Becanex PIEX Bedrocan 70% THC Concentrate. Available in packaging of 50g, 50mL, and 3g units.
2. Contract manufacturing: Becanex produces cannabis extracts on a contract basis (toll manufacturing) for European companies. The company manufactures under its own name and produces extracts for third-party European companies, generating revenue through B2B contract manufacturing services.
3. Distribution partnership revenue: Reciprocal distribution partnership with Four 20 Pharma: Four 20 Pharma adds Becanex's PIEX Concentrates to its product portfolio while Becanex distributes the QMID system and corresponding cartridges. This creates a bidirectional revenue stream through product distribution.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels9 records

Core offering

Becanex manufactures and sells pharmaceutical-grade cannabis crude extracts (PIEX - Plant-Identical Extracts) using its proprietary 1-Step-Extraction process at low temperature and low pressure. The company supplies THC-dominant (70%) and CBD-dominant (62%) concentrates with characterized terpene profiles to compounding pharmacies across Germany and Europe, and produces cannabis extracts on a contract manufacturing basis for European pharmaceutical companies. Becanex is currently the only EU-GMP certified producer of cannabis extracts in Germany.

Product overview

Becanex is a Berlin-based pharmaceutical manufacturer offering the PIEX (Plant-Identical Extracts) product portfolio of cannabis crude extracts. The portfolio comprises THC-dominant concentrates (70% THC, CBD below 1%) and CBD-dominant concentrates (62% CBD, THC below 5%), each derived from specific source flowers (e.g., Strawberry OG for PIEX 2, God Bud for PIEX 3) and featuring characterised terpene profiles. A new Becanex PIEX Bedrocan concentrate extends the partnership portfolio. Products can be combined for patient-specific therapy and are suitable for inhalation, oral, and topical applications. The portfolio is produced using Becanex's proprietary 1-step extraction technology at the EU-GMP certified Berlin facility.

Differentiator

Problem solved

Functional benefit

Brands

• PIEX 2 70% THC Concentrate: THC-dominant plant-identical cannabis concentrate (70% THC, <1% CBD) from Strawberry OG strain, with characteristic terpene profile around 3.5%
• PIEX 3 62% CBD Concentrate
• PIEX 4 70% THC Concentrate
• Becanex PIEX Bedrocan 70% THC Concentrate
• PIEX 6 70% THC Concentrate

Products and services

• Becanex PIEX 1 70% THC Rohextrakt THC cannabis crude extract with 70% THC content and approximately 4% terpene content, serving as an alternative to dronabinol. Features lower viscosity than dronabinol for easier handling and precise dosing. Suitable for inhalation, oral application (capsules, sprays, lozenges, oily solutions), suppositories, and topical preparations. Listed under PZN 195 410 46 in 50mL packaging.
• Becanex PIEX 2 70% THC Rohextrakt THC cannabis crude extract with standardized 70% THC content (CBD below 1%) derived from Strawberry OG cannabis strain. Features batch-stable, characterizing terpene profile with five dominant terpenes representing over 70% of total terpene content (approximately 3.5% total terpenes). Available in 50g or 3g packaging.
• Becanex PIEX 3 62% CBD Rohextrakt CBD cannabis crude extract with standardized 62% CBD content (THC below 5%) derived from God Bud cannabis strain. Features clearly defined terpene profile with five main terpenes representing over 70% of total terpene content (averaging approximately 3%). Minor cannabinoids reported separately for each batch. First CBD crude extract in the German pharmaceutical market. Available in 50g or 3g packaging.
• Becanex PIEX 4 70% THC Rohextrakt Second THC cannabis crude extract in Becanex's portfolio with standardized 70% THC content. Plant-identical with unique terpene profile and flowable viscosity for precise dosing and easy processing. Suitable for standardized extracts, oils, capsules, lozenges, topical applications and inhalation.
• Becanex PIEX 6 70% THC Rohextrakt Third THC cannabis crude extract with standardized 70% THC content. Part of Becanex's long-term stable portfolio including both Indica and Sativa extracts with diverse terpene profiles.
• Becanex PIEX Bedrocan 70% THC Concentrate Jointly developed cannabis extract with Dutch manufacturer Bedrocan, preserving the natural cannabinoid and terpene profile of the original Bedrocan flower. First time the most prescribed Bedrocan flower will be available to pharmacists as a concentrate for bespoke compounding. Suitable for oral solutions, capsules, suppositories, topical forms, and vaporization.
• Contract Cannabis Extract Manufacturing B2B contract (toll) manufacturing of cannabis extracts under EU-GMP standards for European pharmaceutical companies. Becanex manufactures cannabis extracts on a contract basis, generating revenue through professional services for third-party European companies.

Quantifiable outcome

• Up to 89% of terpenes efficiently vaporized — comparable to or better than cannabis flowers — enabling the entourage effect in vaporized form
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• BedrocancoreStrategic or Co-development Partner · 19 May 2026Long-term partnership between Dutch medicinal cannabis pioneer Bedrocan and Berlin-based extraction specialist Becanex. The first jointly developed product is the Becanex PIEX Bedrocan 70% THC Concentrate — the first time the most prescribed Bedrocan flower will be available to pharmacists as a concentrate for bespoke compounding. The product preserves the natural cannabinoid and terpene profile of the original Bedrocan flower through Becanex's proprietary 1-Step-Extraction. The partnership marks the beginning of a broader product collaboration with Germany as the first market. Supply intended to begin summer 2026. Notably, the teams have a historical connection: in 2014, Becanex co-founder Eral Osmanoglou worked with Bedrocan under a scientific licence to develop the first extracts from the Bedrocan flower.
• Four 20 PharmacoreStrategic or Co-development Partner · 20 April 2026Collaboration between Becanex GmbH and Four 20 Pharma GmbH to systematically evaluate the inhalation suitability of Becanex's PIEX concentrates within Curaleaf's Que Medical Inhalation Device (QMID). The objective is a scientifically robust assessment of technical compatibility, aerosol performance, and pharmaceutical quality within a closed, controlled inhalation platform. An initial feasibility study delivered highly positive results. Parallel to the scientific evaluation, a reciprocal distribution partnership was agreed: Four 20 Pharma adds Becanex's PIEX Concentrates to its portfolio while Becanex distributes the QMID system and corresponding cartridges. Four 20 Pharma is a certified manufacturer, importer, and distributor of medical cannabis flowers and full-spectrum extracts and the first to have an approved medical device for inhalable medical cannabis extracts with consistent dosing in Germany.
• Storz & BickelcoreStrategic or Co-development Partner · 4 October 2024Strategic alliance between Becanex (Berlin) and Storz & Bickel (Tuttlingen) to investigate vaporization of Becanex PIEX 70% THC crude extracts using the MIGHTY+ MEDIC and VOLCANO MEDIC 2 vaporizers. The six-month research project analyzed active ingredient release and compatibility between vaporizer and extract. Storz & Bickel is a pioneer in the cannabis industry offering the only certified vaporizers for medical use, while Becanex produces high-THC cannabis crude extracts with flower-like THC and terpene ratios. The combination offers the first real alternative to cannabis flower with rapid active ingredient release. A feasibility study demonstrated up to 89% terpene vaporization efficiency and 64% THC vaporization rate. In January 2026, Storz & Bickel extended the intended use of MIGHTY+ MEDIC and VOLCANO MEDIC 2 to include cannabis raw extracts under MDR Class IIa certification.
• LAGeSo (Berlin State Office for Health and Social Affairs)coreOthers · 1 January 2024Becanex received its manufacturing authorization under §13(1) AMG and GMP certificate per Art. 111(5) of Directive 2001/83/EC from the Berlin State Office for Health and Social Affairs (LAGeSo) in January 2024. This certification is critical for operating as an EU-GMP producer of cannabis extracts in Germany.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Tilray Brands: Global cannabis major with extensive EU medical cannabis operations; broadly competes with Becanex across medical cannabis categories in Germany and Europe, though not specialized in plant-identical pharmaceutical extracts.
• Aurora Cannabis: Canadian cannabis major with European medical cannabis operations including EU-GMP manufacturing; broad incumbent competing in the same end markets as Becanex across extracts and flowers.
• Curaleaf International (formerly EMMAC): European medical cannabis operator with GMP-certified production and the QMID inhalation platform partnered with Becanex; competes as a broad incumbent across EU medical cannabis and now inhalation devices.
• Canopy Growth (Storz & Bickel parent): Parent of Storz & Bickel (Becanex's vaporizer partner) and a global cannabis operator with European medical reach; competes broadly in medical cannabis and now in adjacent inhalation hardware.

Direct peers

• Four 20 Pharma: German certified manufacturer, importer and distributor of medical cannabis flowers and full-spectrum extracts; both a distribution partner and direct competitor in EU-GMP cannabis extract manufacturing for the German market.
• Bedrocan: Dutch pioneer and Europe's most established medicinal cannabis flower producer; both a strategic partner (Bedrocan PIEX concentrate) and a peer that competes as the upstream flower supplier increasingly captured in extract form.
• Demecan: German medicinal cannabis cultivator and producer; one of the few domestic players licensed to grow and process medical cannabis in Germany, directly comparable to Becanex as a domestic German medical cannabis manufacturer.

Regional players

• Cantourage: Berlin-based medical cannabis distributor bringing EU and international cannabis brands into the German pharmacy channel; comparable as a regional player in cannabis supply to German pharmacies.
• Sanity Group: Berlin-headquartered cannabis company with operations across medical and consumer cannabis, including Vayamed for medical cannabis; a regional player competing for the same German medical cannabis distribution.

Emerging players

• Cansativa: Frankfurt-based medical cannabis wholesaler and pharmacy platform; comparable as an emerging player aggregating supply and demand in German medical cannabis distribution.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/becanex
• LinkedInlinkedin.com/company/becanex

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Becanex